---
title: "Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299648083.md"
description: "The latest findings support Avalyn's strategy of administering known antifibrotic drugs directly to the lungs for increased local impact, reducing systemic exposure, and enhancing tolerance."
datetime: "2026-09-21T13:02:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299648083.md)
  - [en](https://longbridge.com/en/news/299648083.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299648083.md)
generator: "portal-rs"
---

# Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile

The latest findings support Avalyn's strategy of administering known antifibrotic drugs directly to the lungs for increased local impact, reducing systemic exposure, and enhancing tolerance.

### Related Stocks

- [AVLN.US](https://longbridge.com/en/quote/AVLN.US.md)

## Related News & Research

- [Avalyn Pharma Inc.'s Lock-Up Period Set To End on October 27th (NASDAQ:AVLN)](https://longbridge.com/en/news/302363456.md)
- [Avalyn Pharma reports Phase 1 data for inhaled nintedanib AP02 showing higher lung exposure, lower systemic levels](https://longbridge.com/en/news/299663715.md)
- [Tesla-SpaceX Merger Stands at 80%-90% Chance, Dan Ives' $500 Price Tag Explains Why](https://longbridge.com/en/news/303112286.md)
- [Verizon CEO Says SpaceX May Be Years Away From Becoming America's 'Sixth' Wireless Competitor](https://longbridge.com/en/news/303109070.md)
- [I'd Buy Half a Position in Amazon Stock Before Its Oct. 29 Report -- and Half After](https://longbridge.com/en/news/303054275.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**